A review of obesity, insulin resistance, and the role of exercise in breast cancer patients

Nutrition and Cancer

Volumn 67, Issue 2, 2015, Pages 197-202

  Ghose, Abhimanyu ^a   Kundu, Ria ^b   Toumeh, Anis ^c   Hornbeck, Catherine ^c   Mohamed, Iman ^c  

^a UNIVERSITY OF CINCINNATI   (United States)

^b GOOD SAMARITAN HOSPITAL   (United States)

^c UNIVERSITY OF TOLEDO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AEROBIC EXERCISE; BODY WEIGHT; BREAST CANCER; CANCER CHEMOTHERAPY; ENDURANCE TRAINING; HUMAN; INSULIN RESISTANCE; OBESITY; REVIEW; WEIGHT GAIN; BREAST NEOPLASMS; COMPLICATION; EXERCISE; FEMALE; METABOLISM; PROGNOSIS; RISK FACTOR;

INSIG1 PROTEIN, HUMAN; MEMBRANE PROTEIN; SIGNAL PEPTIDE;

BREAST NEOPLASMS; EXERCISE; FEMALE; HUMANS; INSULIN RESISTANCE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; OBESITY; PROGNOSIS; RISK FACTORS; WEIGHT GAIN;

EID: 84924523062     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2015.990569     Document Type: Review

References (78)

1. World Health Organization: Noncommunicable Diseases; Cancer; Breast Cancer. Accessed from http://www.emro.who.int/ncd/cancer-breast.htm
2. American Cancer Society: How Many Women Get Breast Cancer? 2014. Accessed from http://www.cancer.org/Cancer/BreastCancer/Overview Guide/breast-cancer-overview-key-statistics
3. Nickels S, Truong T, Hein R, Stevens K, Buck K, et al.: Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet 9(3), e1003284, 2013.
4. Carmichael AR: Obesity and prognosis of breast cancer. Obes Rev 7, 333-340, 2006.
5. Bruning PF, Bonfrer JM, van Noord PA, Hart AA, de Jong-Bakker M, et al.: Insulin resistance and breast-cancer risk. Int J Cancer 52, 511-516, 1992.
6. Caan BJ, Emond JA, Natarajan L, Castillo A, Gunderson EP, et al.: Postdiagnosis weight gain and breast cancer recurrence in women with early stage breast cancer. Breast Cancer Res Treat 99, 47-57, 2006.
7. Kroenke CH, Chen WY, Rosner B, and Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23, 1370-1378, 2005.
8. Rock CL, Flatt SW, Newman V, Caan BJ, Haan MN, et al.: Factors associated with weight gain in women after diagnosis of breast cancer. Women's Healthy Eating and Living Study Group. J Am Diet Assoc 99, 1212-1221, 1999.
9. Rooney M and Wald A: Interventions for the management of weight and body composition changes in women with breast cancer. Clin J Oncol Nurs 11, 41-52, 2007.
10. Heideman WH, Russell NS, Gundy C, Rookus MA, and Voskuil DW: The frequency, magnitude and timing of post-diagnosis body weight gain in Dutch breast cancer survivors. Eur J Cancer 45, 119-126, 2009.
11. Schwartz AL: Exercise and weight gain in breast cancer patients receiving chemotherapy. Cancer Pract 8, 231-237, 2000.
12. Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, et al.: Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol 8, 1327-1334, 1990.
13. Demark-Wahnefried W, Winer EP, and Rimer BK: Why women gain weight with adjuvant chemotherapy for breast cancer. J Clin Oncol 11, 1418-1429, 1993.
14. McTiernan A: Obesity and cancer: the risks, science, and potential management strategies. Oncology (Williston Park) 19, 871-881; discussion, 881-872, 885-876, 2005.
15. Irwin ML, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, et al.: Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 23, 774-782, 2005.
16. Tormey C: Adjuvant systemic therapy in postoperative node-positive patients with breast carcinoma: the CALGB trial and the ECOG premenopausal trial. Recent Results Cancer Res 96, 155-165, 1984.
17. Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, et al.: Tenyear experience with CMF-based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat 5, 95-115, 1985.
18. Rose DP and Davis TE: Ovarian function in patients receiving adjuvant chemotherapy for breast cancer. Lancet 1(8023), :1174-1176, 1977.
19. Heasman KZ, Sutherland HJ, Campbell JA, Elhakim T, and Boyd NF: Weight gain during adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 5, 195-200, 1985.
20. Knobf MK: Weight gain and adjuvant chemotherapy. Oncol Nurs Forum 12, 13, 1985.
21. Bines J, Dienstmann R, Obadia RM, Branco LG, Quintella DC, et al.: Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial. Ann Oncol 25, 831-836, 2014.
22. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, et al.: A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 79, 730-739, 1997.
23. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, et al.: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16, 453-461, 1998.
24. Dal Maso L, Zucchetto A, Talamini R, Serraino D, Stocco CF, et al.: Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer 123, 2188-2194, 2008.
25. Rock CL and Demark-Wahnefried W: Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 20, 3302-3316, 2002.
26. Ryu SY, Kim CB, Nam CM, Park JK, Kim KS, et al.: Is body mass index the prognostic factor in breast cancer?: a meta-analysis. J Korean Med Sci 16, 610-614, 2001.
27. Chlebowski RT, Aiello E, and McTiernan A: Weight loss in breast cancer patient management. J Clin Oncol 20, 1128-1143, 2002.
28. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, et al.: Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 111, 762-771, 2004.
29. Weiderpass E, Braaten T, Magnusson C, Kumle M, Vainio H, et al.: A prospective study of body size in different periods of life and risk of premenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 13, 1121-1127, 2004.
30. Stephenson GD and Rose DP: Breast cancer and obesity: an update. Nutr Cancer 45, 1-16, 2003.
31. DeFronzo RA and Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14, 173-194, 1991.
32. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, et al.: Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 119, 236-238, 2006.
33. Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, et al.: Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11, 1361-1368, 2002.
34. Schairer C, Hill D, Sturgeon SR, Fears T, Pollak M, et al.: Serum concentrations of IGF-I, IGFBP-3 and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer 108, 773-779, 2004.
35. Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, et al.: Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 26, 1752-1758, 2003.
36. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, et al.: Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20, 42-51, 2002.
37. Healy LA, Ryan AM, Carroll P, Ennis D, Crowley V, et al.: Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol) 22, 281-288, 2010.
38. Mathieu MC, Clark GM, Allred DC, Goldfine ID, and Vigneri R: Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians 109, 565-571, 1997.
39. Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, et al.: Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19, 3278-3288, 1999.
40. Yamaguchi Y, Flier JS, Yokota A, Benecke H, Backer JM, et al.: Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese hamster ovary cells. Endocrinology 129, 2058-2066, 1991.
41. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, et al.: A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 87, 245-254, 2002.
42. Girnita L, Girnita A, Brodin B, Xie Y, Nilsson G, et al.: Increased expression of insulin-like growth factor I receptor in malignant cells expressing aberrant p53: functional impact. Cancer Res 60, 5278-5283, 2000.
43. Papa V and Belfiore A: Insulin receptors in breast cancer: biological and clinical role. J Endocrinol Invest 19, 324-333, 1996.
44. Patel NM, Nozaki S, Shortle NH, Bhat-Nakshatri P, Newton TR, et al.: Paclitaxel sensitivity of breast cancer cells with constitutively active NFkappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 19, 4159-4169, 2000.
45. Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, et al.: Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. Intern Med 38, 202-206, 1999.
46. Rajala MW and Scherer PE: Minireview: The adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144, 3765-3773, 2003.
47. Railo MJ, von Smitten K, and Pekonen F: The prognostic value of insulinlike growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 30A, 307-311, 1994.
48. Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, et al.: The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 183, 412-417, 1997.
49. Foekens JA, Portengen H, van Putten WL, Trapman AM, Reubi JC, et al.: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49(24, Pt. 1), 7002-7009, 1989.
50. Bhatavdekar JM, Patel DD, Karelia NH, Vora HH, Ghosh N, et al.: Tumor markers in patients with advanced breast cancer as prognosticators: a preliminary study. Breast Cancer Res Treat 30, 293-297, 1994.
51. Verheus M, Peeters PH, Rinaldi S, Dossus L, Biessy C, et al.: Serum Cpeptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 119, 659-667, 2006.
52. Redig AJ and Munshi HG: Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy. Am J Med 123, e81-86, 2010.
53. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, et al.: Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 91, 2906-2912, 2006.
54. Gonzalez-Angulo AM and Meric-Bernstam F: Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 16, 1695-1700, 2010.
55. Maiti B, Kundranda MN, Spiro TP, and Daw HA: The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat 121, 479-483, 2010.
56. Holmes MD, Chen WY, Feskanich D, Kroenke CH, and Colditz GA: Physical activity and survival after breast cancer diagnosis. JAMA 293, 2479-2486, 2005.
57. Pinto BM and Maruyama NC: Exercise in the rehabilitation of breast cancer survivors. Psychooncology 8, 191-206, 1999.
58. Bianchini F, Kaaks R, and Vainio H: Weight control and physical activity in cancer prevention. Obes Rev 3, 5-8, 2002.
59. Kramer JA, Curran D, Piccart M, de Haes JC, Bruning P, et al.: Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36, 1498-1506, 2000.
60. KirshbaumMN: A review of the benefits of whole body exercise during and after treatment for breast cancer. J Clin Nurs 16, 104-121, 2007.
61. Ohira T, Schmitz KH, Ahmed RL, and Yee D: Effects of weight training on quality of life in recent breast cancer survivors: the Weight Training for Breast Cancer Survivors (WTBS) study. Cancer 106, 2076-2083, 2006.
62. De Backer IC, Schep G, Backx FJ, Vreugdenhil G, and Kuipers H: Resistance training in cancer survivors: a systematic review. Int J Sports Med 30, 703-712, 2009.
63. Henriksen EJ: Exercise training and the antioxidant alpha-lipoic acid in the treatment of insulin resistance and type 2 diabetes. Free Radic Biol Med 40, 3-12, 2006.
64. Perez-Martin A, Raynaud E, and Mercier J: Insulin resistance and associated metabolic abnormalities in muscle: effects of exercise. Obes Rev 2, 47-59, 2001.
65. Goulet ED, Melancon MO, Aubertin-Leheudre M, and Dionne IJ: Aerobic training improves insulin sensitivity 72-120 h after the last exercise session in younger but not in older women. Eur J Appl Physiol 95, 146-152, 2005.
66. Christ-Roberts CY, Pratipanawatr T, Pratipanawatr W, Berria R, Belfort R, et al.: Exercise training increases glycogen synthase activity and GLUT4 expression but not insulin signaling in overweight nondiabetic and type 2 diabetic subjects. Metabolism 53, 1233-1242, 2004.
67. Oh EG, Chu SH, Bang SY, Lee MK, Kim SH, et al.: Effects of a therapeutic lifestyle modification program on inflammatory chemokines and insulin resistance in subjects with metabolic syndrome. Biol Res Nurs 13, 182-188, 2011.
68. Chen CN, Chuang LM, and Wu YT: Clinical measures of physical fitness predict insulin resistance in people at risk for diabetes. Phys Ther88, 1355-1364, 2008.
69. Schmitz KH, Ahmed RL, Hannan PJ, and Yee D: Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomarkers Prev 14, 1672-1680, 2005.
70. Fairey AS, Courneya KS, Field CJ, Bell GJ, Jones LW, et al.: Effects of exercise training on fasting insulin, insulin resistance, insulin-like growth factors, and insulin-like growth factor binding proteins in postmenopausal breast cancer survivors: a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 12, 721-727, 2003.
71. Ligibel JA, Campbell N, Partridge A, Chen WY, Salinardi T, et al.: Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol 26, 907-912, 2008.
72. Arikawa AY, Kurzer MS, Thomas W, and Schmitz KH: No effect of exercise on insulin-like growth factor-I, insulin, and glucose in young women participating in a 16-week randomized controlled trial. Cancer Epidemiol Biomarkers Prev 19, 2987-2990, 2010.
73. Battaglini C, Bottaro M, Dennehy C, Rae L, Shields E, et al.: The effects of an individualized exercise intervention on body composition in breast cancer patients undergoing treatment. Sao Paulo Med J 125, 22-28, 2007.
74. Shang J, Wenzel J, Krumm S, Griffith K, and Stewart K: Who will drop out and who will drop in: exercise adherence in a randomized clinical trial among patients receiving active cancer treatment. Cancer Nurs 35, 312-322, 2012.
75. Pickett M, Mock V, Ropka ME, Cameron L, Coleman M, et al.: Adherence to moderate-intensity exercise during breast cancer therapy. Cancer Pract 10, 284-292, 2002.
76. Oldervoll LM, Loge JH, Paltiel H, Asp MB, Vidvei U, et al.: The effect of a physical exercise program in palliative care: A phase II study. J Pain Symptom Manage 31, 421-430, 2006.
77. Rajarajeswaran P and Vishnupriya R: Exercise in cancer. Indian J Med Paediatr Oncol 30, 61-70, 2009.
78. Segal R, Evans W, Johnson D, Smith J, Colletta S, et al.: Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. J Clin Oncol 19, 657-665, 2001.